CMS advises Bruker on its investment in Navignostics

Bruker Corporation, a NASDAQ-listed US tech company in the analytical instrumentation sector, invests in Navignostics. Bruker led the CHF 7.5 million seed financing round, which was also joined by Think.Health Ventures, Ventura Biomed Investors and Zürcher Kantonalbank.

Navignostics strives to support the selection of targeted and immuno-oncology therapies tailored to the tumour phenotype of individual cancer patients by using artificial intelligence driven software combined with single-cell resolved spatial proteomic tumour data. The funding will strengthen Navignostics' ability to collaborate with clinical, biotechnology and pharmaceutical partners and accelerate the development of its first diagnostic product.

A team from CMS Switzerland, led by partner Stefan Brunnschweiler, advised Bruker on all legal matters of the transaction. Bruker is a longstanding CMS client and has been advised by CMS on several acquisitions and disposals in the past.

CMS Switzerland

• Stefan Brunnschweiler, Partner, Corporate / M&A
• Pascal Stocker, Associate, Corporate / M&A
• Dr Simone Brauchbar Birkhäuser, Counsel, Intellectual Property
• Hadi Mirzai, Associate, Life Sciences and Competition
• Sarah Keller, Associate, Employment